Radiolabeled PD-L1-binding molecules, capable of capturing the entire extent of tumor heterogeneity, have been introduced as tracers to visualize PD-L1 expression in tumor-bearing animals and patients with NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.